Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer
Weekly Low-dose Paclitaxel (Phyxol) Plus 24-Hour Infusion of Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Chiun Hsu, M.D., Ph.D.
- Phone Number: 7009 886-2-23123456
- Email: chiunhsu@ha.mc.ntu.edu.tw
Study Contact Backup
- Name: Yen-Shen Lu, M.D.
- Phone Number: 7009 886-2-23123456
- Email: yslu@ha.mc.ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- Department of Oncology , National Taiwan University Hospital
-
Contact:
- Yen-Shen Lu, M.D.
- Phone Number: 7009 886-2-23123456
- Email: yslu@ha.mc.ntu.edu.tw
-
Sub-Investigator:
- Sung-Hsin Kuo, M.D.
-
Sub-Investigator:
- Chia-Chi Lin, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with histologically proven breast cancer and clinical evidence of distant metastasis
- The index lesions should be at least 20 mm × 20 mm in size
- Age must be older than 18 and younger than 75 year-old
- Karnofsky performance status > 70%
- Adequate bone marrow reserves, defined as white blood cell (WBC) > 4,000, absolute neutrophil count (ANC) > 1,500, platelet > 100,000
- Liver transaminases < 3 times upper normal limit if no liver metastasis and 5 times upper normal limit if liver metastasis is present; total bilirubin < 2 mg/dl; serum creatinine < 1.5 mg/dl
- No prior chemotherapy for metastatic disease. Previous chemotherapy as adjuvant treatment is acceptable, if the adjuvant chemotherapy has been completed at least 6 months before entry into in this study
- If the patients have received hormonal therapy for metastatic disease, there must be definite evidence of disease progression under the hormonal therapy, and hormonal therapy should be discontinued before entry into this study
- Previous or concurrent radiotherapy is acceptable if the area of radiation does not involve the site of the index tumor lesions
- Patients of childbearing age should have effective contraception during the study period
- All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional guidelines.
Exclusion Criteria:
- Patients who are receiving concurrent hormonal or cytotoxic therapy or other experimental therapy. Concurrent therapy with other biological agents, such as Trastuzumab (Herceptin), is not allowed
- Patients who refuse port-A catheter implantation
- Patients who have received taxane (paclitaxel or docetaxel) or cisplatin as adjuvant chemotherapy
- Patients with brain or leptomeningeal metastases
- Patients who have significant cardiac arrhythmia or acute myocardial infarction within 6 months before entry
- Patients who have major systemic diseases that the attending physicians considered inappropriate for systemic chemotherapy
- Life expectancy less than 2 months
- Pregnant or nursing patients may not participate. Patients with reproductive potential may not participate unless they have agreed to use an effective contraceptive method
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancers, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any cancer from which the patient has been disease-free for 5 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary endpoint of this phase II trial is the objective response rate of the stage I (low-dose) regimen.
Time Frame: 2003~2008
|
2003~2008
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The secondary endpoints include treatment-related toxicity, the change in quality of life, progression free survival and overall survival.
Time Frame: 2003~2008
|
2003~2008
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yen-Shen Lu, M.D., Department of Oncology , National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 920705
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.